These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34953683)

  • 1. Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure.
    Patoulias D; Papadopoulos C; Doumas M
    J Stroke Cerebrovasc Dis; 2022 Mar; 31(3):106257. PubMed ID: 34953683
    [No Abstract]   [Full Text] [Related]  

  • 2. A meta-analysis of randomized controlled trials evaluating sodium-glucose co-transporter 2 inhibitors and incidental atrial fibrillation-Is there a true benefit?
    Mishriky BM; Cummings DM; Powell JR
    Diabetes Metab Res Rev; 2024 Jan; 40(1):e3715. PubMed ID: 37649368
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure.
    Attachaipanich T; Chattipakorn SC; Chattipakorn N
    J Cell Physiol; 2022 May; 237(5):2404-2419. PubMed ID: 35324001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Pandey AK; Okaj I; Kaur H; Belley-Cote EP; Wang J; Oraii A; Benz AP; Johnson LSB; Young J; Wong JA; Verma S; Conen D; Gerstein H; Healey JS; McIntyre WF
    J Am Heart Assoc; 2021 Sep; 10(17):e022222. PubMed ID: 34459238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
    Nana M; Morgan H; Bondugulapati LNR
    Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
    Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
    [No Abstract]   [Full Text] [Related]  

  • 7. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
    Okunrintemi V; Mishriky BM; Powell JR; Cummings DM
    Diabetes Obes Metab; 2021 Jan; 23(1):276-280. PubMed ID: 33001548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!
    Katsiki N; Rizzo M; Mikhailidis DP
    J Diabetes Complications; 2023 Jul; 37(7):108510. PubMed ID: 37235924
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
    Garla V; Subauste A; Butler J; Lien LF
    J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia.
    Khan MS; Butler J; Greene SJ
    Circ Heart Fail; 2020 Dec; 13(12):e008030. PubMed ID: 33161728
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to: Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Yalta
    Joshi SS; Singh T; Singh J; Newby DE
    Heart; 2021 Dec; 107(23):1922-1923. PubMed ID: 34656972
    [No Abstract]   [Full Text] [Related]  

  • 13. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
    Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC
    Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089
    [No Abstract]   [Full Text] [Related]  

  • 14. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
    Butler J; Anker SD; Filippatos G; Usman MS; Ferreira JP; Zannad F; Packer M
    Eur Heart J; 2021 Dec; 42(48):4887-4890. PubMed ID: 34718518
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latest news on heart failure and atrial fibrillation from the European Society Of Cardiology Congress 2020.
    Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):343-344. PubMed ID: 33002119
    [No Abstract]   [Full Text] [Related]  

  • 17. Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure.
    Liang B; Gu N
    Cardiovasc Diabetol; 2022 May; 21(1):84. PubMed ID: 35624512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.
    Honigberg MC; Vardeny O; Vaduganathan M
    Circ Heart Fail; 2020 Feb; 13(2):e006623. PubMed ID: 32059632
    [No Abstract]   [Full Text] [Related]  

  • 19. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
    Butler J; Handelsman Y; Bakris G; Verma S
    Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.